Neurobiological Technologies

Last updated

Neurobiological Technologies, Inc. ("NTI") was a biotechnology company that was founded in 1987 by Enoch Callaway and John B. Stuppin to in-license and develop drugs primarily to treat neurological conditions; the company was dissolved in 2009 after the failure of its drug candidate ancrod in a Phase III trial for ischemic stroke. [1] [2] [3]

The company pursued a virtual company model from the beginning, keeping staff as small as possible and outsourcing tasks to contract research organizations and contract manufacturing organizations. [4] [5]

At the time the company made its first public offering in 1996, it had three products in development: memantine, a small molecule for neuropathic pain and AIDS-related dementia, corticotropin-releasing factor, a biopharmaceutical to treat edema caused by brain tumors and inflammation caused by rheumatoid arthritis, and dynorphin A, a biopharmaceutical to treat pain. [1] It licensed patents covering methods to use memantine from Children's Hospital of Boston in 1995. [1]

In 1997 the company hired Paul Frieman as its CEO—Frieman was an experienced executive who had sold his biotech company three years before for $5.4B. [6] Frieman cut staff from 23 people to 9, and in 1998 amended NTI's agreement with Children's Hospital of Boston to allow the German company Merz Pharma, which had been marketing memantine in Europe for dementia since 1989 and was running similar clinical trials to those run by NTI, to take over development. [6] [7] Merz paid NTI $2.1M upfront and agreed to pay both NTI and Children's Hospital royalties. [7] [8]

In 2000 Merz partnered with Forest Laboratories to further develop memantine, and NTI received about $8 million from the upfront payment. [9] That money covered the approximately $5 million that NTI had put into development of memantine. [10]

In 2004 NTI acquired Empire Pharmaceuticals, which had one product: ancrod (Viprinex). [11] Empire had been formed by former employees of Knoll Pharmaceuticals, the German company that had discovered and started developing ancrod, and had acquired the rights to ancrod in 2002, after Knoll's acquisition by Abbott Laboratories in 2001. [11] [12] : 5  [13] NTI also acquired a batch of unpurified venom in the acquisition, and had that purified for use in its clinical trials. [10] [14]

Ancrod became NTI's lead product; in 2006 Frieman estimated annual sales $500 million to $1 billion. [10]

The company collapsed when a Phase III trial of ancrod was halted early in December 2008 when an independent review committee looked at the interim data and found no signal of benefit. [15] [16] [17] One of its main investors was the Biotechnology Value Fund, which put pressure on the company to dissolve and pay out its investors. [18] It cut staff in early 2009, then sought to sell off its assets, and finally dissolved in August 2009. [2] [17] [19]

The company's CEOs were:

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

<span class="mw-page-title-main">Memantine</span> Medication used to treat moderate-to-severe Alzheimers disease

Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.

<span class="mw-page-title-main">Exelixis</span> American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Ancrod is a defibrinogenating agent derived from the venom of the Malayan pit viper. Defibrinogenating blood produces an anticoagulant effect. Ancrod is not approved or marketed in any country. It is a thrombin-like serine protease.

Nuvelo Inc. was a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. On January 27, 2009, the company was acquired by ARCA Biopharma, Inc. in a reverse takeover transaction.

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

Christoph Westphal is an American biomedical businessman.

GTx, Inc. is a pharmaceutical company that is working on drugs in the selective estrogen receptor modulator (SERM) and selective androgen receptor modulator (SARM) classes. Its drugs in development include enobosarm (ostarine) and GTx-758.

Knoll Pharmaceuticals was a drug development company founded by Albert Knoll and Hans Knoll in Germany in 1886. The company was taken over by German BASF in 1975, which sold it to Abbott Laboratories on 30 June 2002 for $6.9 billion.

<span class="mw-page-title-main">Galena Biopharma</span>

Galena Biopharma was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc.

<span class="mw-page-title-main">Incyte</span> American pharmaceutical company

Incyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Acceleron Pharma</span> American healthcare company

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

<span class="mw-page-title-main">Arbutus Biopharma</span> Canadian Bio Tech Company

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

<span class="mw-page-title-main">Amicus Therapeutics</span> Pharmaceutical company

Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.

Roivant is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies, founded by Vivek Ramaswamy.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

References

  1. 1 2 3 "Form 10-KSB For the fiscal year ended June 30, 1996". SEC Edgar. September 30, 1996. NTI-Children's license is included in the filing.
  2. 1 2 Brown, Steven E.F.; Leuty, Ron (August 31, 2009). "Neurobiological Technologies to dissolve". San Francisco Business Times.
  3. ↑ "Neurobiological Technologies Inc.: CEO and Executives - Bloomberg". Bloomberg. Archived from the original on 5 February 2017. Retrieved 5 February 2017.
  4. ↑ Welles, Edward O. (January 1, 1995). "The Awakening". Inc.
  5. ↑ Eichenwald, Kurt; Kolata, Gina (16 May 1999). "Drug Trials Hide Conflicts for Doctors". The New York Times.
  6. 1 2 Delevett, Peter (January 9, 2000). "Cash is king, focus is queen". Silicon Valley Business Journal.
  7. 1 2 Rauber, Chris (April 26, 1998). "A midget in the land of giants, Omni seeks a savior r". San Francisco Business Journal.
  8. ↑ "Exhibit 10.1: License and Cooperation Agreement". SEC Edgar.
  9. ↑ "Merz + Co and Forest link up for memantine". The Pharma Letter. July 6, 2000.
  10. 1 2 3 Smith, Aaron (February 24, 2006). "California biotech looking in snakes' mouths for stroke drug - Feb. 24, 2006". CNN Money.
  11. 1 2 "Neurobiological Tech buys Empire Pharma". The Pharma Letter. July 26, 2004.
  12. ↑ "Form 10-K For the fiscal year ended June 30, 2007". NTI via SEC Edgar. September 13, 2007.
  13. ↑ "Exhibit 10.18 License Agreement between Empire and Abbott, March 29, 2002". Law Insider.
  14. ↑ "Exhibit 10.1: Cooperation and Supply Agreement". NTI via SEC Edgar. Retrieved 5 February 2017.
  15. ↑ Asadi, H; Yan, B; Dowling, R; Wong, S; Mitchell, P (2014). "Advances in medical revascularisation treatments in acute ischemic stroke". Thrombosis. 2014: 714218. doi: 10.1155/2014/714218 . PMC   4293866 . PMID   25610642.
  16. ↑ Hao, Z; Liu, M; Counsell, C; Wardlaw, JM; Lin, S; Zhao, X (14 March 2012). "Fibrinogen depleting agents for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (3): CD000091. doi:10.1002/14651858.CD000091.pub2. PMID   22419274.
  17. 1 2 Carroll, John (December 17, 2008). "Neurobiological Tech halts enrollment, prepares cuts". FierceBiotech.
  18. ↑ "DealBook: Drug Investors Lose Patience". New York Times. March 10, 2009.
  19. ↑ Myers, Calisha (January 13, 2009). "Neurobiological Technologies, Inc. (NTII) Ends Stroke Drug Development; Cuts Jobs". FierceBiotech.
  20. ↑ "Schedule 14a: Notice of Meeting and Proxy Statement". SEC Edgar. October 11, 1996.
  21. ↑ Leuty, Ron (July 2, 2008). "Neurobiological Technologies' Freiman to retire". San Francisco Business Journal.
  22. ↑ Myers, Calisha (February 4, 2009). "Neurobiological Technologies, Inc. Announces Appointment of William A. Fletcher as Acting CEO". FierceBiotech.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.